Donor Type Does Not Impact Late Graft Failure Following Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis.
Saved in:
| Title: | Donor Type Does Not Impact Late Graft Failure Following Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis. |
|---|---|
| Authors: | Hickey CL; Memorial University of Newfoundland, Division of Hematology, Newfoundland, Canada., Zhang MJ; Division of Biostatistics, Data Science Institute, Medical College of Wisconsin, Milwaukee, Wisconsin; CIBMTR (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, Wisconsin., Allbee-Johnson M; CIBMTR (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, Wisconsin., Romee R; Dana-Farber Cancer Institute, Division of Transplantation and Cellular Therapy, Boston, Massuchusetts., Majhail NS; Sarah Cannon Transplant and Cellular Therapy Network, Nashville, Tennessee., Malki MMA; City of Hope, Department of Hematology and Hematopoietic Cell Transplantation, Duarte, California., Antin JH; Dana-Farber Cancer Institute, Division of Transplantation and Cellular Therapy, Boston, Massuchusetts., Benjamin CL; University of Miami Miller School of Medicine, Department of Medicine, Miami, Florida., Bredeson C; Ottawa Hospital TCT Programme and Ottawa Hospital Research Institute, Ottawa, Ontario, Canada., Chhabra S; Division of Hematology/Oncology, Department of Medicine, Mayo Clinic Arizona, Phoenix, AZ., Grunwald MR; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina., Inamoto Y; Department of BMT & Cellular Therapy, Fujita Health University School of Medicine, Toyoake, Japan., Kanakry CG; Center for Immuno-Oncology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland., Milano F; Fred Hutchinson Cancer Center, Translational Science and Therapeutics Division, Seattle, Washington., Soiffer RJ; Dana Farber Institute, Division of Hematologic Malignancies, Boston, Massachusetts., Solomon SR; Blood and Marrow Transplant Program, Northside Hospital Cancer Institute, Atlanta, Georgia., Spellman SR; CIBMTR (Center for International Blood and Marrow Transplant Research), National Marrow Donor Program (NMDP), Minneapolis, Minnesota., Brunstein CG; Cleveland Clinic, Taussig Cancer Institute, Department of Hematology and Oncology, Cleveland, Ohio., Cutler C; Dana-Farber Cancer Institute, Division of Transplantation and Cellular Therapy, Boston, Massuchusetts. Electronic address: corey_cutler@dfci.harvard.edu. |
| Source: | Transplantation and cellular therapy [Transplant Cell Ther] 2025 Mar; Vol. 31 (3), pp. 174.e1-174.e12. Date of Electronic Publication: 2025 Jan 02. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101774629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-6367 (Electronic) Linking ISSN: 26666367 NLM ISO Abbreviation: Transplant Cell Ther Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
